Orexin-A Research

Orexin-A, also called hypocretin-1, is a 33-residue neuropeptide made in the hypothalamus. Orexin-A research splits into two bodies of work that are easy to confuse. One measures the peptide in people, and it is large, replicated and clinically entrenched. The other administers the peptide to people, and its published record is four small crossover studies. Almost everything persuasive about orexin-A belongs to the first.

What orexin-A is

Two groups described the peptide independently in 1998. Sakurai and colleagues named orexin-A and orexin-B, and reported that both derive from one precursor and activate two G protein-coupled receptors ^[1]. De Lecea and colleagues described the same hypothalamic peptides as the hypocretins, and both naming systems remain in use ^[2].

Orexin-B, or hypocretin-2, is a different peptide from the same precursor with a different receptor preference ^[1]. Evidence on orexin-B is not evidence on orexin-A. Suppliers list Orexin-A under CAS 205640-90-0, while the PubChem compound record for the same molecule carries CAS 205599-75-3, and both numbers designate orexin-A.

Mechanism, and the approved drugs at these receptors

Orexin-A activates the orexin receptors OX1R and OX2R, while orexin-B prefers OX2R ^[1]. Sakurai and colleagues localized the precursor to the lateral and posterior hypothalamus in rat brain ^[1]. The suvorexant label describes orexin A and orexin B as wake-promoting neuropeptides.

The three FDA-approved insomnia drugs in this field run the opposite way. Suvorexant, lemborexant and daridorexant are orexin receptor antagonists, approved for insomnia under NDA204569, NDA212028 and NDA214985. The suvorexant label states that blocking the binding of orexin A and orexin B to OX1R and OX2R is thought to suppress wake drive. Those products work by blocking what orexin-A does, and their approvals and clinical data do not transfer to the peptide.

The agonist direction now has an approved drug of its own. Oveporexton, also called TAK-861, is an oral OX2R agonist approved for narcolepsy type 1 under NDA220860 ^[19]. It is a small molecule and not the peptide, and its approval is evidence that developers went around orexin-A rather than through it.

Danavorexton is another small-molecule OX2R agonist that points the same way as orexin-A without being it. In a phase 1b human crossover in idiopathic hypersomnia, a single infusion improved wakefulness and sleepiness measures against placebo ^[3]. Of 28 randomized human participants, 12 had a treatment-emergent adverse event and 10 had one judged related to study drug ^[3]. Most of those events were mild or moderate ^[3]. Four human participants had urinary adverse events while receiving danavorexton, and all of those were mild ^[3]. The trial reported no deaths and no adverse events leading to discontinuation ^[3]. That trial was sponsored by Takeda, which develops the molecule ^[3]. Its results are evidence about a small molecule, not about the peptide.

Measuring orexin-A is not administering it

Low cerebrospinal fluid orexin-A is the defining marker of narcolepsy type 1, and that finding is well replicated in humans. Nishino and colleagues reported in 2000 that hypocretin-1 was undetectable in the CSF of most human narcolepsy-cataplexy patients ^[4]. Peyron and colleagues found a generalized absence of hypocretin peptides in human narcoleptic brains post mortem, alongside one early-onset case carrying a precursor mutation ^[5]. Mignot and colleagues then established CSF measurement as a diagnostic test across narcolepsy and other hypersomnias, in 274 human subjects ^[6].

Those are measurement studies, and they describe a missing peptide rather than testing what giving one does. The literature on administering orexin-A to people is far smaller.

Preclinical orexin-A research

The preclinical work on nasal orexin-A includes one widely cited nonhuman primate study. Deadwyler and colleagues gave orexin-A to sleep-deprived rhesus monkeys and reported improved delayed match-to-sample performance, with the nasal route outperforming the highest intravenous exposure tested ^[7]. The benefit was specific to high cognitive load trials. In alert, non-sleep-deprived monkeys neither route changed performance, except at that highest intravenous exposure ^[7]. The equivalent human sleep-deprivation experiment has never been published.

The preclinical pharmacokinetics contradict each other. In anesthetized rats, Dhuria and colleagues reported that intranasal hypocretin-1 reached brain concentrations similar to intravenous despite far lower blood levels ^[8]. They attributed roughly 80 percent of brain exposure to direct nose-to-brain transport ^[8]. Van de Bittner and colleagues then imaged carbon-11-labeled orexin-A by PET, in rodents and in nonhuman primates ^[9]. They concluded that brain exposure to orexin A is poor in those animals after intranasal administration ^[9]. Their ex vivo animal work in the same paper found intranasal brain uptake similar to intravenous across most regions, with possible enrichment only in the olfactory bulbs ^[9].

Both papers are peer reviewed and neither has been retracted, and no published work has adjudicated between them.

What human orexin-A research shows

The published record of administering orexin-A to people is four crossover studies, in which thirty-nine participants received the peptide. No further human administration study appears in the PubMed-indexed record. Non-indexed and non-English work was not searched.

Baier and colleagues reported in 2008 that intranasal orexin A improved 2-phenyl-ethyl alcohol odor detection against placebo in human narcolepsy with cataplexy ^[10]. The odor threshold score rose in those human patients after orexin A, and a higher score on that measure means better detection ^[10]. Seven patients received the peptide in that study.

Baier and colleagues then tested the wake-promoting hypothesis directly, in eight human patients, and it failed. Intranasal hypocretin-1 had no statistically significant effect on nocturnal wakefulness ^[11]. What moved were secondary measures, namely reduced REM sleep quantity in the second half of the night and fewer direct wake-to-REM transitions ^[11]. The authors themselves call it a pilot study.

Weinhold and colleagues ran the largest of the four, in fourteen human patients ^[12]. They reported fewer wake-REM transitions, decreased REM duration, increased N2 duration the following night, and fewer false reactions on a divided attention test ^[12]. A 2024 systematic review of orexin treatment in narcolepsy type 1 screened 70 records and included only these three trials ^[13]. Its scope was narcolepsy type 1, so the healthy-volunteer sympathetic study fell outside it ^[13]. It records that Weinhold's maintenance of wakefulness testing showed no change in daytime awake time ^[13]. It also records that neither the 2011 nor the 2014 trial differed from placebo on the Stanford Sleepiness Scale ^[13]. Its discussion states that none of the trials showed changes in the length of daytime wakefulness ^[13]. That review is a secondary source rather than new human data ^[13].

Across the whole human record of administering orexin-A, no study has reported a wakefulness benefit.

The one study in healthy volunteers produced a safety signal rather than a benefit. Meusel and colleagues reported that intranasal orexin A significantly increased resting muscle sympathetic nerve activity against placebo in ten healthy human males ^[14]. Burst rate rose by 5.8 versus 2.1 bursts per minute, and total activity reached 169 versus 115 percent ^[14]. Blood pressure, heart rate and baroreflex sensitivity were unchanged ^[14]. The authors read this as an upward resetting of the vascular baroreflex set point, and call for investigation of the orexin system in neurogenic arterial hypertension ^[14].

The 2024 review notes that none of the three narcolepsy trials reported any incident or undesirable side effect ^[13]. That does not offset the sympathetic finding, which came from a different population and a different endpoint. The healthy-volunteer study enrolled young lean men only, so it carries no sympathetic-response data in women or in older people ^[14]. No repeat-exposure human safety data exists for this peptide. No human safety data in people with cardiovascular disease exists for this peptide.

None of the four studies measured whether orexin-A reached the human central nervous system. Every human behavioral result therefore rests on a delivery assumption that the PET study contradicts ^[9].

Who produced the evidence

All four human administration studies come from German academic groups, led from Kiel and Lübeck, and three authors each appear on three of the four ^{[10][11][12][14]}. No independent group has published a human intranasal orexin-A study, and no attempt to replicate the narcolepsy findings has appeared since 2014.

The olfactory premise behind the 2008 study has not held up. Ghielmini and colleagues could not confirm decreased olfaction in human narcolepsy with cataplexy, and found olfactory discrimination correlated negatively with momentary sleepiness ^[15]. Buskova and colleagues found olfactory dysfunction in human narcolepsy without cataplexy as well, where most cases have normal CSF hypocretin ^[16]. Bayard and colleagues ran the largest olfactory study in human narcolepsy with cataplexy, in 130 patients against 129 controls ^[17]. They found a real but modest deficit, with no case of anosmia or severe hyposmia ^[17]. Among those human patients, the olfactory identification deficit was significant in the Italian cohort and not significant in the French cohort ^[17].

One editorial has been published directly on these trials from outside the German groups. Lammers, a co-author of the original CSF deficiency reports and of none of the intranasal studies, wrote an editorial comment on the 2011 trial in the same issue ^[18].

One conflict of interest in this literature runs against interest. The PET study reporting poor intranasal brain exposure carries seven Sanofi US author affiliations and one from Impel NeuroPharma, an intranasal drug delivery company ^[9]. It also carries Massachusetts General Hospital authorship and NIH grant support ^[9]. So a company did pursue orexin-A preclinically, and a nasal delivery firm co-authoring a negative result about nasal delivery makes that negative harder to discount.

Regulatory status

Orexin-A is not an approved drug in the United States. Drugs@FDA queries for orexin and for hypocretin as active ingredients return no application of any kind, while the identical query for suvorexant returns NDA204569. So this is neither a withdrawn approval nor a refused one, and no marketing application was ever filed. Non-US regulators were not queried directly, and no evidence of approval elsewhere was found.

ClinicalTrials.gov holds no registered study in which orexin-A itself is the intervention. The four human studies were investigator-initiated academic work, and whether they were entered on the German national trials register has not been checked.

Two records invite misreading. The FDA and NCATS substance registry lists orexin A with a record status of "approved", which is the curation status of a substance definition rather than a marketing authorization. A LOINC code also exists for orexin-A, and it identifies a laboratory assay rather than a drug.

Conclusion

Orexin-A has almost thirty years of mechanistic research behind it and a large human diagnostic literature. Its published administration record is four small crossover studies from one national research community, none of them independently replicated and none of them registered on ClinicalTrials.gov. Whether they were entered on the German national trials register has not been checked. The flagship wakefulness endpoint came back null, and the strongest result against the delivery premise is an animal PET study reporting poor brain exposure by the nasal route.

Frequently Asked Questions

Is orexin-A approved, given that suvorexant and daridorexant are? Orexin-A is not an approved drug in the United States, and Drugs@FDA holds no application of any kind for it. Suvorexant, lemborexant and daridorexant are FDA-approved for insomnia, under NDA204569, NDA212028 and NDA214985. All three are orexin receptor antagonists, and they block the receptors orexin-A activates. An OX2R agonist is now approved for narcolepsy type 1, oveporexton under NDA220860, but it is a small molecule and not the peptide ^[19]. None of those approvals is orexin-A's approval.

Does human research show that orexin-A promotes wakefulness? Across the whole human record of administering orexin-A, no study has reported a wakefulness benefit. The 2011 trial found no statistically significant effect on nocturnal wakefulness ^[11]. A 2024 systematic review states that none of the three narcolepsy trials showed changes in the length of daytime wakefulness ^[13].

Does the CSF orexin-A finding in narcolepsy show that giving the peptide works? Those are two different bodies of evidence. Low CSF orexin-A is a diagnostic marker of narcolepsy type 1, established by human measurement studies ^[4][5][6]. Those studies describe a missing peptide and do not test administration.

Are orexin-A, hypocretin-1 and orexin-B the same thing? Orexin-A and hypocretin-1 are two names for one peptide, from two groups that described it independently in 1998 ^[1][2]. Orexin-B, or hypocretin-2, is a different peptide from the same precursor with a different receptor preference ^[1]. Evidence on orexin-B is not evidence on orexin-A. Suppliers list orexin-A under CAS 205640-90-0, while the PubChem compound record for the same molecule carries CAS 205599-75-3.

References

1. 1

   Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JR, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma DJ, Yanagisawa M. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92(4):573-85. PMID 9491897
2. 2

   de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, Fukuhara C, Battenberg EL, Gautvik VT, Bartlett FS 2nd, Frankel WN, van den Pol AN, Bloom FE, Gautvik KM, Sutcliffe JG. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A. 1998;95(1):322-7. PMID 9419374
3. 3

   Mignot E, Bogan RK, Emsellem H, Foldvary-Schaefer N, Naylor M, Neuwirth R, Faessel H, Swick T, Olsson T. Safety and pharmacodynamics of a single infusion of danavorexton in adults with idiopathic hypersomnia. Sleep. 2023;46(9):zsad049. PMID 36883238
4. 4

   Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000;355(9197):39-40. PMID 10615891
5. 5

   Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, Nevsimalova S, Aldrich M, Reynolds D, Albin R, Li R, Hungs M, Pedrazzoli M, Padigaru M, Kucherlapati M, Fan J, Maki R, Lammers GJ, Bouras C, Kucherlapati R, Nishino S, Mignot E. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med. 2000;6(9):991-7. PMID 10973318
6. 6

   Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S, Overeem S, Vankova J, Black J, Harsh J, Bassetti C, Schrader H, Nishino S. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002;59(10):1553-62. PMID 12374492
7. 7

   Deadwyler SA, Porrino L, Siegel JM, Hampson RE. Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci. 2007;27(52):14239-47. PMID 18160631
8. 8

   Dhuria SV, Hanson LR, Frey WH 2nd. Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system. J Pharm Sci. 2009;98(7):2501-15. PMID 19025760
9. 9

   Van de Bittner GC, Van de Bittner KC, Wey HY, Rowe W, Dharanipragada R, Ying X, Hurst W, Giovanni A, Alving K, Gupta A, Hoekman J, Hooker JM. Positron Emission Tomography Assessment of the Intranasal Delivery Route for Orexin A. ACS Chem Neurosci. 2018;9(2):358-368. PMID 29035509
10. 10

    Baier PC, Weinhold SL, Huth V, Gottwald B, Ferstl R, Hinze-Selch D. Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal Orexin A (Hypocretin-1). Brain. 2008;131(Pt 10):2734-41. PMID 18718966
11. 11

    Baier PC, Hallschmid M, Seeck-Hirschner M, Weinhold SL, Burkert S, Diessner N, Göder R, Aldenhoff JB, Hinze-Selch D. Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy. Sleep Med. 2011;12(10):941-6. PMID 22036605
12. 12

    Weinhold SL, Seeck-Hirschner M, Nowak A, Hallschmid M, Göder R, Baier PC. The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy. Behav Brain Res. 2014;262:8-13. PMID 24406723
13. 13

    Thomaz TG, McBenedict B, Meireles DK, Farias GF, Almeida LC, de Almeida Leitão MC, Hauwanga WN, Lima Pessôa B, do Nascimento MI. Treatment of Narcolepsy Type 1 With Orexin: A Systematic Review. Cureus. 2024;16(12):e76692. PMID 39898129
14. 14

    Meusel M, Voß J, Krapalis A, Machleidt F, Vonthein R, Hallschmid M, Sayk F. Intranasal orexin A modulates sympathetic vascular tone: a pilot study in healthy male humans. J Neurophysiol. 2022;127(2):548-558. PMID 35044844
15. 15

    Ghielmini E, Poryazova R, Baumann CR, Bassetti CL. Sleepiness at the time of testing impairs olfactory performance. Eur Neurol. 2013;69(1):58-64. PMID 23146877
16. 16

    Buskova J, Klaschka J, Sonka K, Nevsimalova S. Olfactory dysfunction in narcolepsy with and without cataplexy. Sleep Med. 2010;11(6):558-61. PMID 20513636
17. 17

    Bayard S, Plazzi G, Poli F, Serra L, Ferri R, Dauvilliers Y. Olfactory dysfunction in narcolepsy with cataplexy. Sleep Med. 2010;11(9):876-81. PMID 20817549
18. 18

    Lammers GJ. Intranasal hypocretin-1: making sense of scents? Sleep Med. 2011;12(10):939-40. PMID 22136855
19. 19

    Sun Y, Gao J. Oveporexton: the first-in-class orexin receptor 2 (OX2R) agonist approved for treatment of narcolepsy type 1 (NT1). Drug Discov Ther. 2026 Aug 19. PMID 42618292